Zilretta (Triamcinolone Acetonide) Patent Expiration, LOE Window & CMS Spending

Zilretta (Triamcinolone Acetonide) by Pacira: FDA Orange Book LOE 2031-08-04, 9 AB generics, $6.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPacira
FDA Application & PathwayN208845 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-08-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$6.3M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$4.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel